ArticleThe Journal of allergy and clinical immunology2012
Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes.
Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Serum matters: human platelet lysate enables physiological modeling of HIV-1 infection in dendritic cells.Frontiers in immunology · 2025Article
- Is the Complement System Dysregulated in Preeclampsia Comorbid with HIV Infection?International journal of molecular sciences · 2024Review
- Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies.The EMBO journal · 2024Article
- HIV-1Biomolecules · 2022Article
- Article
- Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.Frontiers in immunology · 2021Article
- Innate Immune Response Against HIV-1.Advances in experimental medicine and biology · 2021Article
- CR4 Signaling Contributes to a DC-Driven Enhanced Immune Response Against Complement-Opsonized HIV-1.Frontiers in immunology · 2020Article
- In the Crosshairs: RNA Viruses OR Complement?Frontiers in immunology · 2020Review
- Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity.Frontiers in immunology · 2020Review
- β-1,3-glucan-lackingVirulence · 2019Article
- Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity.FEMS microbiology reviews · 2019Review
- Article
- Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity.Frontiers in immunology · 2019Article
- Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Frontiers in immunology · 2017Review
- Generation of Human Monocyte-derived Dendritic Cells from Whole Blood.Journal of visualized experiments : JoVE · 2016Article
- Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.Emerging microbes & infections · 2016Review
- Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells.PLoS pathogens · 2015Article
- Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity.Frontiers in immunology · 2015Review
- Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundControl of HIV is suggested to depend on potent effector functions of the virus-specific CD8(+) T-cell response. Antigen opsonization can modulate the capture of antigen, its presentation, and the priming of specific CD8(+) T-cell responses.
objectiveWe have previously shown that opsonization of retroviruses acts as an endogenous adjuvant for dendritic cell (DC)-mediated induction of specific cytotoxic T lymphocytes (CTLs). However, in some HIV-positive subjects, high levels of antibodies and low levels of complement fragments coat the HIV surface.
methodsTherefore we analyzed the effect of IgG opsonization on the antigen-presenting capacity of DCs by using CD8(+) T-cell proliferation assays after repeated prime boosting, by measuring the antiviral activity against HIV-infected autologous CD4(+) T cells, and by determining IFN-γ secretion from HIV-specific CTL clones.
resultsWe find that DCs exposed to IgG-opsonized HIV significantly decreased the HIV-specific CD8(+) T-cell response compared with the earlier described efficient CD8(+) T-cell activation induced by DCs loaded with complement-opsonized HIV. DCs exposed to HIV bearing high surface IgG levels after incubation in plasma from HIV-infected subjects acted as weak stimulators for HIV-specific CTL clones. In contrast, HIV opsonized with plasma from patients exhibiting high complement and low IgG deposition on the viral surface favored significantly higher activation of HIV-specific CD8(+) T-cell clones.
conclusionOur ex vivo and in vitro observations provide the first evidence that IgG opsonization of HIV is associated with a decreased CTL-stimulatory capacity of DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.